Home / GU oncology / Prostate / Early salvage RT post-prostatectomy

Prostate → Early salvage radiotherapy after prostatectomy

Last reviewed: 2026-09-22 · Next review: 2026-12-21

current — early salvage radiotherapy is most effective at low PSA; systemic and nodal intensification must match trial risk boundaries

Who this applies to

Population	Direct-evidence boundary	Not established by the pivotal data
Detectable or rising PSA after prostatectomy	Confirm PSA trajectory, pathology, testosterone, conventional/PSMA imaging when clinically appropriate, and absence of known metastases⁴⁵.	Do not treat disparate PSA entry windows as identical populations¹².
GETUG-AFU 16 population	pT2–4a, pN0/x, rising PSA 0.1–2.0 ng/mL, no clinical disease¹.	Node-positive, overt metastatic, or PSA-outside-window disease¹.
RTOG 9601 population	pT2 margin-positive or pT3, N0, PSA 0.2–4.0 ng/mL².	An exclusively very-low-PSA population².

Standard options

Clinical context	Option	Key inclusion	Typical duration
Biochemical recurrence after prostatectomy	Early salvage prostate-bed radiotherapy⁴	AUA/ASTRO/SUO recommends treatment by PSA ≤0.5 ng/mL and allows consideration below 0.2 ng/mL for high-risk patients⁴.	Field and dose individualized⁴.
High-risk features with salvage radiotherapy	Add ADT¹²⁴	Higher-risk features include PSA ≥0.7 ng/mL, Grade Group 4–5, PSADT ≤6 months, persistent PSA, or seminal-vesicle involvement in guideline framing⁴.	At least 4–6 months when used; longer duration may be considered for high risk¹²⁴.
Selected nodal-risk disease	Pelvic-node plus prostate-bed radiotherapy with short-course ADT³	Match the SPPORT population and discuss incremental toxicity³.	SPPORT used 4–6 months ADT³.

Therapy sequencing

Recurrence state	Treatment order	Evidence boundary
Rising or persistent PSA after prostatectomy	Evaluate PSA kinetics, pathology, testosterone, and imaging → early salvage prostate-bed radiotherapy at low PSA⁴.	Early salvage is not a substitute for metastatic treatment when staging establishes distant disease⁴⁵.
High-risk features with salvage radiotherapy	Add ADT to prostate-bed radiotherapy¹²⁴.	Duration should match the risk and pivotal trial boundary; GETUG-AFU 16 does not establish long-course ADT for every patient¹.
Selected nodal-risk disease	Prostate-bed plus pelvic-node radiotherapy with 4–6 months ADT³.	SPPORT is a three-arm trial; it does not isolate a radiation-field effect without ADT³.
PET-detected distant disease or progression after salvage	Move to a metastatic systemic-therapy pathway⁵.	This page does not establish a preferred systemic sequence after salvage radiotherapy⁵.

Surveillance and treatment de-escalation

Phase	Monitoring cadence	Stop, hold, or de-escalate	Re-escalation / next line
Before and during salvage RT⁴	PSA, testosterone, and imaging to exclude distant disease; treat at PSA ≤0.5 ng/mL when feasible (≤0.2 ng/mL for high-risk features per society guidance)⁴.	Complete radiotherapy course; ADT duration matches trial (GETUG-AFU 16: two goserelin injections; RTOG 9601: 24 months bicalutamide; SPPORT: 4–6 months ADT with nodal fields)¹²³.	Progression after salvage → ADT intensification, metastatic systemic therapy, or repeat local assessment⁴⁵.
After salvage RT ± ADT⁴	PSA every 3–6 months; monitor ADT side effects and bone health⁴⁶.	Stop short-course ADT at planned end; long-course bicalutamide completes 24 months unless toxicity¹²³.	Rising PSA with imaging-confirmed metastases → mHSPC/mCRPC pathways⁵.

Pelvic-node radiotherapy plus short ADT (SPPORT) is for selected nodal-risk disease; do not extend nodal fields without trial-consistent indications³.

Published 120-month PFS 64% vs 49% (SRT+short ADT vs SRT); not a full KM reconstruction¹.

Landmark evidence

Trial	Population	Intervention	Comparator	Primary endpoint	Clinically meaningful outcomes	Generalizability-critical differences
GETUG-AFU 16	pT2–4a, pN0/x, PSA 0.1–2.0, no clinical disease¹	Salvage radiotherapy plus two goserelin injections¹	Salvage radiotherapy¹	Progression-free survival¹	120-month PFS 64% vs 49%; HR 0.54 (0.43–0.68)¹.	Short-course ADT study; does not define long-course ADT value¹.
RTOG 9601	pT2 margin-positive or pT3, N0, PSA 0.2–4.0²	Salvage radiotherapy plus 24 months bicalutamide²	Salvage radiotherapy plus placebo²	Overall survival²	12-year OS 76.3% vs 71.3%; HR 0.77 (0.59–0.99)².	Higher PSA window and 24-month bicalutamide strategy; not an exclusively low-PSA trial².
SPPORT	pT2–3, N0/x, PSA 0.1–2.0³	Pelvic-node plus prostate-bed radiotherapy plus 4–6 months ADT³	Prostate-bed radiotherapy alone³	Five-year freedom from progression³	87.4% vs 70.9%; intermediate arm with prostate-bed RT plus ADT was 81.3%³.	Three-arm trial; the node-field benefit is not an isolated radiation-only comparison³.

Biomarkers

Marker	Current clinic role	Emerging / investigational	How it changes decision now	Limits
PSA and PSA doubling time	Defines recurrence kinetics and intensification risk⁴	—	Serial PSA guides early salvage timing (treat by ≤0.5 ng/mL when feasible); PSADT ≤6 months is among high-risk features favoring ADT with salvage RT in guideline framing⁴.	Do not substitute PSA kinetics for staging or a trial entry window¹²⁴.
PSMA PET	Staging and target-definition information⁴⁵	Expanding use at low PSA before salvage⁴⁵	Helps exclude distant disease and may refine fields when clinically appropriate⁴⁵.	Negative imaging does not exclude microscopic disease; match treatment to clinical risk and evidence boundary⁴.
Pathology	Risk assessment for ADT and field discussion⁴	—	Grade Group, seminal-vesicle involvement, margin, and nodal status inform counseling and intensification⁴.	Pathology alone does not replace PSA timing or imaging assessment⁴.
Testosterone	Confirms castration status when ADT is used or considered⁴	—	Document before and during salvage ± ADT; stop short-course ADT at planned end¹²³⁴.	Not a selector among salvage-field strategies⁴.

Upcoming research

Field direction: PET-directed intensification of salvage radiotherapy and systemic therapy is the main care-changing research track after biochemical recurrence⁸.

Trial	Why it may change care	Evidence status
EA8191 / INDICATE	Tests PET-directed systemic/local intensification against salvage radiotherapy plus short-term ADT after biochemical recurrence⁸.	Recruiting phase 3; PFS primary endpoint; no outcomes reported⁸.

Toxicity

Regimen and comparator	Trial-level safety outcomes	Selected named toxicities	Counseling focus
Salvage radiotherapy plus goserelin versus radiotherapy, GETUG-AFU 16	Late grade ≥3 GU events: 7% vs 8%¹.	Grade ≥2 hot flushes 8% vs none; sexual disorders 8% vs 5%¹.	Counsel on hot flashes, sexual effects, urinary symptoms, and treatment-related fatigue¹.
Salvage radiotherapy plus bicalutamide versus radiotherapy, RTOG 9601	The retrieved source set does not provide a table-wide grade ≥3 rate².	Gynecomastia 69.7% vs 10.9%².	Discuss breast symptoms, sexual effects, urinary/bowel toxicity, and prompt review of troublesome effects².
SPPORT intensification, SPPORT	Acute grade ≥2 AEs 18%, 36%, and 44% across the three arms³.	Grade ≥3 event values were not supplied in the retrieved abstract³.	Discuss added acute urinary/bowel effects with pelvic-node treatment and ADT³.

On-treatment monitoring

SOC/option regimen	Hallmark monitoring toxicity and published rate	Patient action / clinic response
Salvage radiotherapy plus goserelin	GETUG-AFU 16: late grade ≥3 GU events 7% vs 8%; grade ≥2 hot flushes 8% vs none¹.	Monitor urinary/bowel symptoms, hot flashes, sexual function, fatigue, metabolic and bone effects; urinary retention, heavy bleeding, or severe bowel symptoms needs prompt contact¹.
Salvage radiotherapy plus bicalutamide	RTOG 9601: gynecomastia 69.7% vs 10.9%².	Review breast symptoms, sexual effects, urinary/bowel symptoms, and fatigue; troublesome breast pain or swelling, retention, heavy bleeding, or severe bowel symptoms needs prompt contact².
Prostate-bed plus pelvic-node radiotherapy with short-course ADT	SPPORT: acute grade ≥2 AEs 18%, 36%, and 44% across the three arms; the retrieved abstract did not report a comparable grade ≥3 named rate³.	Monitor added acute urinary/bowel symptoms and ADT effects; severe diarrhea, retention, heavy bleeding, or dehydration needs prompt contact³.

Epic phrase

#postprostatectomysalvage

Counseling: GETUG-AFU 16 added short ADT to salvage RT: 10-year progression-free survival about 64% vs 49% with RT alone (HR 0.54 vs RT alone). RTOG 9601: 12-year overall survival 76.3% with 24 months bicalutamide vs 71.3% with placebo (HR 0.77 vs placebo). SPPORT pelvic-node RT plus short ADT: 5-year freedom from progression 87.4% vs 70.9% with prostate-bed RT alone. Early treatment at low PSA improves outcomes.
Counseling: Reviewed surveillance and de-escalation: treat at low PSA (≤0.5 ng/mL when feasible); complete planned short or long ADT per trial boundary; post-salvage PSA every 3–6 months; imaging-confirmed metastases → systemic pathway. GETUG-AFU 16 published 120-month PFS about 64% vs 49% with RT alone when short ADT was added (not a full KM curve).
Counseling: Reviewed sequence: evaluate PSA kinetics/pathology/testosterone/imaging → early salvage prostate-bed radiotherapy; add ADT for high-risk features; use pelvic-node treatment with short-course ADT for the selected SPPORT-like population; metastatic disease moves to a systemic pathway. ***
Monitoring: Review hot flashes, breast symptoms with bicalutamide, urinary/bowel effects, fatigue, sexual effects, and bone/metabolic effects with ADT. Contact oncology or radiation oncology for urinary retention, heavy bleeding, severe bowel symptoms, or intolerable treatment effects.
Decision: *** selects prostate-bed salvage radiotherapy / salvage radiotherapy plus ADT / pelvic-node plus prostate-bed radiotherapy with ADT / further staging or trial evaluation.
Labs/NGS: PSA *, testosterone *, pathology *; PSMA PET *.
Procedures: *** radiation-oncology and multidisciplinary review.
Follow-up: *** PSA response, ADT toxicity, urinary/bowel symptoms, and imaging plan.

Edit markdown

Guideline references

Sources

Changelog

2026-09-22: Inserted GETUG-AFU 16 120-month PFS landmark figure; expanded Biomarkers to five-column clinic/emerging format (PSA/PSADT, PSMA PET, pathology, testosterone).
2026-09-22: Renamed Upcoming trial results to Upcoming research; reframed for ongoing trials and field direction.
2026-09-22: Named comparator arms in paired dotphrase counseling for efficacy/toxicity rates.
2026-09-22: Added line-level source superscripts ([^n]) linked to numbered Sources.
2026-09-22: Added Surveillance and treatment de-escalation section; strengthened quantified benefit counseling in dotphrase.

2026-09-21: Added early-salvage sequencing and radiotherapy/ADT monitoring tables.
2026-09-21: Created early-salvage radiotherapy page with source-verified intensification evidence and toxicity counseling.

Edit evidence markdown

Evidence page